Enhanced Combination Therapy for Coronavirus Infections

Publication ID: 24-11857617_0001_PTD

Published: October 28, 2025

Category:Direct Improvements & Enhancements

Legal Citation

pr1or.art Inc., “Enhanced Combination Therapy for Coronavirus Infections,” Published Technical Disclosure No. 24-11857617_0001_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857617_0001_PTD

This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,617.

Summary of the Inventive Concept

The present invention relates to improved methods and systems for treating and preventing coronavirus infections through a combination of anti-viral drugs and vaccines, addressing limitations of existing treatments by reducing vaccine breakthrough infections, enhancing vaccine efficacy, and minimizing adverse effects.

Background and Problem Solved

The original patent disclosed methods for treating coronavirus infections using a combination of antibiotics, anti-viral drugs, and vaccines. However, these methods had limitations, including the potential for vaccine breakthrough infections, reduced vaccine efficacy, and adverse effects. The present invention addresses these limitations by introducing novel formulations, dosing regimens, and monitoring systems to improve treatment outcomes.

Detailed Description of the Inventive Concept

The inventive concept comprises methods and systems for treating and preventing coronavirus infections using a combination of anti-viral drugs and vaccines. In one embodiment, an anti-viral drug combination is formulated to prevent in vivo mutations of the causative agent, reducing the likelihood of vaccine breakthrough infections. In another embodiment, a system for treating coronavirus infections includes an antibiotic and/or anti-viral drug, a vaccine directed to a coronavirus, and a means for monitoring and adjusting the dosage of the antibiotic and/or anti-viral drug based on the individual's immune response. The inventive concept also includes methods for enhancing the efficacy of a vaccine against a coronavirus infection by administering an anti-viral drug combination to prevent replication of newly-inhaled mutants in the already vaccinated individual.

Novelty and Inventive Step

The present invention's novelty lies in its ability to prevent vaccine breakthrough infections, enhance vaccine efficacy, and minimize adverse effects through the use of novel formulations, dosing regimens, and monitoring systems. The inventive step is the recognition that a combination of anti-viral drugs and vaccines, when formulated and dosed in a specific manner, can address the limitations of existing treatments and provide improved treatment outcomes.

Alternative Embodiments and Variations

Alternative embodiments of the inventive concept may include different formulations of the anti-viral drug combination, varying dosing regimens, and alternative monitoring systems. Variations may also include the use of different vaccines or anti-viral drugs, or the incorporation of additional therapeutic agents to enhance treatment outcomes.

Potential Commercial Applications and Market

The present invention has significant commercial potential in the treatment and prevention of coronavirus infections, with a target market including pharmaceutical companies, healthcare providers, and government agencies. The inventive concept's ability to reduce vaccine breakthrough infections, enhance vaccine efficacy, and minimize adverse effects makes it an attractive solution for addressing the ongoing pandemic and future coronavirus outbreaks.

CPC Classifications

Section	Class	Group
A	A61	A61K39/12
A	A61	A61K31/166
A	A61	A61K45/06
A	A61	A61P31/14
C	C12	C12N7/00
A	A61	A61K2039/545

Section 103 Obviousness Analysis (PHOSITA)

▼

Field of Art

Medical virology, immunology, and pharmaceutical treatment of viral infections, with expertise in vaccine development, antiviral drug combinations, and infectious disease management

Person of Ordinary Skill (PHOSITA) Profile

A medical researcher or clinician with advanced degrees in virology or pharmacology, experienced in developing combination therapies, understanding viral mutation mechanisms, and designing treatment protocols for infectious diseases

Obviousness Rationale

A person skilled in the art would recognize that the PTD's variations represent predictable extensions of the source patent's core methodology of combining antiviral drugs and vaccines. The proposed modifications address known challenges in viral infection treatment, such as breakthrough infections and vaccine efficacy, using standard techniques of drug combination and dosage optimization that would be apparent to a skilled practitioner in the field.

Obvious Combinations & Variations

Source Patent Element

Method of administering anti-viral drug combination with a vaccine for coronavirus infection

PTD Variation

Adding a specific mechanism to prevent in vivo mutations of the causative agent

Obviousness Reasoning

Preventing viral mutations is a known goal in infectious disease treatment, and a PHOSITA would find it obvious to modify existing combination therapies to address mutation risks using standard virological techniques

Source Patent Element

Dosage ranges for anti-viral drugs like doxycycline and zinc

PTD Variation

Implementing a dynamic dosage adjustment system based on individual immune response

Obviousness Reasoning

Personalized medicine and adaptive dosing are well-established approaches in clinical treatment, representing a predictable optimization of the existing drug administration method

Source Patent Element

Timing of drug and vaccine administration within a 14-day window

PTD Variation

Staggered regimen specifically designed to prevent breakthrough infections

Obviousness Reasoning

Modifying administration timing to enhance vaccine effectiveness is a logical and predictable approach that would be obvious to a skilled practitioner seeking to improve treatment outcomes

Source Patent Element

Combination of anti-viral drugs and vaccines for coronavirus treatment

PTD Variation

Targeting specific coronavirus epitopes to reduce viral load and adverse effects

Obviousness Reasoning

Epitope-specific targeting is a standard technique in vaccine and treatment design, representing an obvious refinement of existing combination therapy approaches

Source Patent Element

Basic method of treating coronavirus infections

PTD Variation

Creating a comprehensive kit with integrated administration instructions

Obviousness Reasoning

Packaging medical treatments with clear instructions is a common pharmaceutical practice, representing a straightforward and obvious product development strategy

35 U.S.C. § 103 Summary: Based on the teachings of US Patent 11857617, the variations disclosed in this published technical disclosure would be considered obvious to a person having ordinary skill in the art of viral infection treatment. The proposed modifications represent predictable extensions of existing combination therapy methodologies, utilizing standard techniques in drug administration, vaccine design, and personalized medical treatment that would be readily apparent to a skilled practitioner in the field of infectious disease management.

Original Patent Information

Patent Number	US 11,857,617
Title	Methods for treating, ameliorating or preventing infections using drug and vaccination combination treatment
Assignee(s)	TOPELIA AUST LIMITED (652 771 670)